Milad Alucozai

Revalia Bio is a seed series start-up spun out of Yale with 20M funding, 30M government contracts, and 40M research grants. Revalia Bio is seeking to revolutionize biomedical innovation by creating the worlds first integrated human data stack.

Talus Bio is making the regulome visible and druggable. We are building the first platform to map, model, and ultimately write the regulome, unlocking thousands of previously undruggable targets, including transcription factors that drive cancer, autoimmunity, and neurodegeneration. Our platform measures the regulome directly in living human cells, generating functional datasets at scale for the first time. These data fuel AI models that learn the logic of genome regulation and predict how to modulate it with precision.

bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable research and drug discovery teams to accelerate their experimental timelines and reduce experimental variability, providing an important alternative to traditional workflows. We are also leveraging our platform to build a pipeline of txCells for cell therapies. To achieve our goals, we have assembled a team of pioneers in stem cell biology, cell programming, mathematical modelling and cell therapy. We are empirical, highly ambitious and driven by a shared vision. Collaboration is at the heart of bit.bio. Join us on our journey. For more information on bit.bio’s trademarks, visit www.bit.bio/trademarks

Mekonos is a Silicon Valley Venture-backed Life Sciences company — creating a proprietary cell-engineering platform based on scalable silicon technology for our partners engaged in cell & gene therapies and cell line development.

Seqera is on a mission to simplify complex data analysis pipelines in the cloud. We provide software that enables developers and data scientists to create and deploy data applications in any environment. Our core, open-source technology Nextflow transforms the building of massively scalable and distributed computing solutions. Seqera is now empowering customers across pharma, genomics and biotech to break with the status quo of closed-platforms and custom scripts to embrace the future of cloud.

Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.

An early-stage, operator-led venture fund that acts as the first check and full-stack partner for technical pioneers building AI-focused companies. We firmly believe the next wave of billion-dollar companies will emerge from AI-focused, incredibly lean and nimble teams. As a full-stack partner, not merely a capital provider, we are the first call for founders with extremely strong technical and academic backgrounds. We build deep trust and guide these technical pioneers to become world-class operators. Our hands-on engagement helps our founders transform industries with capital-efficient AI, generating outsized returns for our LP’s in the process.

At the Wyss Institute, we leverage recent insights into how Nature builds, controls and manufactures to develop new engineering innovations - a new field of research we call Biologically Inspired Engineering. Our scientists, engineers and clinicians, who come from Harvards Schools of Medicine, Engineering, Arts & Sciences, Design, and Education as well as 12 collaborating academic institutions and hospitals, work alongside staff with industrial experience in product development to engineer transformative solutions to some of the world’s greatest problems. By emulating biological principles of self assembly, organization and regulation, we are developing disruptive technology solutions for healthcare, energy, architecture, robotics, and manufacturing, which are translated into commercial products and therapies through formation of new startups and corporate alliances.

Revalia Bio is a seed series start-up spun out of Yale with 20M funding, 30M government contracts, and 40M research grants. Revalia Bio is seeking to revolutionize biomedical innovation by creating the worlds first integrated human data stack.

Talus Bio is making the regulome visible and druggable. We are building the first platform to map, model, and ultimately write the regulome, unlocking thousands of previously undruggable targets, including transcription factors that drive cancer, autoimmunity, and neurodegeneration. Our platform measures the regulome directly in living human cells, generating functional datasets at scale for the first time. These data fuel AI models that learn the logic of genome regulation and predict how to modulate it with precision.